The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia

Hypomethylating agents (HMAs) have been used for decades in the treatment of hematologic neoplasms, and now, have gathered attention again in terms of their combination with potent molecular-targeted agents such as a BCL-6 inhibitor venetoclax and an <i>IDH1</i> inhibitor ivosidenib, as...

Full description

Bibliographic Details
Main Authors:	Akiko Urabe, SungGi Chi, Yosuke Minami
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	International Journal of Molecular Sciences
Subjects:	hypomethylating agents acute myeloid leukemia PD-1 CD47
Online Access:	https://www.mdpi.com/1422-0067/24/4/3727

Similar Items

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
by: Alicia Roldán Pérez, et al.
Published: (2022-07-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance
by: Rahul Mishra, et al.
Published: (2023-12-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
by: Hussein Awada, et al.
Published: (2023-04-01)

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
by: Giovanni Marconi, et al.
Published: (2023-05-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia
by: Luciana Melo Garcia, et al.
Published: (2021-12-01)

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
by: Smith Kungwankiattichai, et al.
Published: (2022-02-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
by: Xubo Gong, et al.
Published: (2024-02-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
by: Xubo Gong, et al.
Published: (2023-06-01)

Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies
by: Andrealuna Ucciero, et al.
Published: (2023-09-01)

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
by: Carmelo Gurnari, et al.
Published: (2020-11-01)

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
by: Audrey Delmas, et al.
Published: (2023-05-01)

Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01)

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
by: Aleksina Shatilova, et al.
Published: (2021-05-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia
by: Shuya Feng, et al.
Published: (2024-02-01)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
by: Emmanuella Oyogoa, et al.
Published: (2023-07-01)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Kah Keng Wong, et al.
Published: (2021-02-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
by: Giulia Ciotti, et al.
Published: (2022-01-01)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01)

The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study
by: Dan Liu, et al.
Published: (2023-01-01)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
by: Jorge Labrador, et al.
Published: (2022-05-01)

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis
by: Yufeng Du, et al.
Published: (2023-08-01)

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
by: Johanna Rausch, et al.
Published: (2023-09-01)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
by: Chryssoula Kordella, et al.
Published: (2021-03-01)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
by: Yifan Liu, et al.
Published: (2023-11-01)

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia
by: Nancy D. Ebelt, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Yasmin Abaza, et al.
Published: (2022-07-01)

Emerging Immunotherapy for Acute Myeloid Leukemia
by: Rikako Tabata, et al.
Published: (2021-02-01)

Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
by: Hironori Arai, et al.
Published: (2022-11-01)

Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia
by: Andrew H. Matthews, et al.
Published: (2022-11-01)

Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis
by: David Beauvais, et al.
Published: (2022-10-01)

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
by: Naval G. Daver, et al.
Published: (2023-03-01)

Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study
by: Kriti Gera, et al.
Published: (2023-08-01)

Uncommon CD markers in acute myeloid leukemia
by: Azad Abul Kalam, et al.
Published: (2018-12-01)